Lawrence Fong, MDEnriched profile
Physician; Scientific Director, Immunotherapy Integrated Research Center; Professor, Translational Science and Therapeutics, Fred Hutch Cancer Center; Professor of Medicine, Division of Hematology and Oncology, University of Washington · Fred Hutch Cancer Center
Overview
Updated 14 Jul 2026
Lawrence Fong, MD, is Physician at Fred Hutchinson Cancer Center. The public record shows 771 publications with 35,122 citations (h-index 75), centered on Cancer Immunotherapy and Biomarkers, Prostate Cancer Treatment and Research, Immunotherapy and Immune Responses. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 18 companies, 1 NIH-funded awards (2024–2025).
- Most recent indexed publication: 2026 · Nature cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 18 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 217.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
Sponsor: MedPacto, Inc.
InvestigatorPhase 2WithdrawnNCT04064190 - Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Sponsor: Lawrence Fong
InvestigatorPhase 2TerminatedNCT03007719 - Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Sponsor: Lawrence Fong
InvestigatorPhase 2TerminatedNCT02506114
Industry payments
Updated 14 Jul 2026
18 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments$20,636openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim RCV GmbH & Co KGProgram year20251 payment
- ROCHE MOLECULAR SYSTEMS, INC.Program year20257 payments
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2024–2025 per NIH RePORTER. The latest:
- Determinants of response to cancer immunotherapy
Fred Hutchinson Cancer Center
FY2025$1,055,838R35CA253175 - Project 1-Combination Immunotherapy with Radioligned Therapy for Metastatic Prostate Cancer
University of California, San Francisco
FY2025$529,989P50CA275741 - Determinants of response to cancer immunotherapy
Fred Hutchinson Cancer Center
FY2024$1,002,984R35CA253175
Congress activity
Updated 14 Jul 2026
147 congress contributions (2006–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Abstract 4325: FXYD5 plays diverse roles in immune evasion and tumor progression in prostate cancer
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Functionally heterogeneous intratumoral CD4(+)CD8(+) double-positive T cells can give rise to single-positive T cells.
Proceedings of the National Academy of Sciences of the United States of America
2026 - Tumor cell heterogeneity drives spatial organization of the intratumoral immune response.
The Journal of experimental medicine
2025
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1100 Fairview Ave. N., Seattle, WA 98109
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Editorial & leadership rolesjournal and society appointments
- Scientific Director
Immunotherapy Integrated Research Center, Fred Hutch Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Elected Member
Board of Directors, Society for Immunotherapy of Cancer (SITC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - Inaugural Senior Editor
Cancer Immunology Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
- National Cancer Institute Outstanding Investigator Award
2021 ($4.2 million over 7 years, "Determinants of Response to Cancer Immunotherapy")
2021verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗
Secondary affiliationsappointments beyond the home institution
- Professor of Medicine
Division of Hematology and Oncology, University of Washington School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hemonc.uw.edu ↗
Media & interviewspress, podcasts and appearances
- "Dr. Lawrence Fong, new Fred Hutch immunotherapy director, talks about how the field has transformed oncology"
Fred Hutch News feature/Q&A, August 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - "Dr. Lawrence Fong to lead Immunotherapy Integrated Research Center"
Fred Hutch News feature, October 2023
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fredhutch.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/lawrence-fong-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Brenda Sandmaier, MD
Fred Hutch Cancer Center
- 670
- publications
- 92
- h-index
- 22
- trials
Petros Grivas, MD, PhD
Fred Hutch Cancer Center
- 910
- publications
- 62
- h-index
- 6
- trials